BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baqi Y, Müller CE. Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. Drug Discov Today 2019;24:325-33. [PMID: 30291899 DOI: 10.1016/j.drudis.2018.09.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian M, Abdelrahman A, Baqi Y, Fuentes E, Azazna D, Spanier C, Densborn S, Hinz S, Schmid R, Müller CE. Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists. J Med Chem 2020;63:6164-78. [PMID: 32345019 DOI: 10.1021/acs.jmedchem.0c00435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schöneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 2020;177:2413-33. [PMID: 32037507 DOI: 10.1111/bph.15005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 26.0] [Reference Citation Analysis]
3 Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 2021;6:162. [PMID: 33907179 DOI: 10.1038/s41392-021-00553-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Lei Y, Zhang B, Liu D, Zhao J, Dai X, Gao J, Mao Q, Feng Y, Zhao J, Lin F, Duan Y, Zhang Y, Bao Z, Yang Y, Mou Y, Wang S. Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y 1 and P2Y 12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor. J Med Chem 2020;63:15752-72. [DOI: 10.1021/acs.jmedchem.0c01524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Liu ZQ. Bridging free radical chemistry with drug discovery: A promising way for finding novel drugs efficiently. Eur J Med Chem 2020;189:112020. [PMID: 32006794 DOI: 10.1016/j.ejmech.2019.112020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee CH, Franchi F, Angiolillo DJ. Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol 2020;16:1079-96. [PMID: 32835535 DOI: 10.1080/17425255.2020.1814254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Müller CE, Namasivayam V. Recommended tool compounds and drugs for blocking P2X and P2Y receptors. Purinergic Signal 2021;17:633-48. [PMID: 34476721 DOI: 10.1007/s11302-021-09813-7] [Reference Citation Analysis]
8 von Kügelgen I. Molecular pharmacology of P2Y receptor subtypes. Biochem Pharmacol 2021;187:114361. [PMID: 33309519 DOI: 10.1016/j.bcp.2020.114361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 von Kügelgen I. Pharmacology of P2Y receptors. Brain Res Bull 2019;151:12-24. [PMID: 30922852 DOI: 10.1016/j.brainresbull.2019.03.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
10 Cao X, Du X, Jiao H, An Q, Chen R, Fang P, Wang J, Yu B. Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.020] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Jacobson KA, IJzerman AP, Müller CE. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. Biochem Pharmacol 2021;187:114311. [PMID: 33130128 DOI: 10.1016/j.bcp.2020.114311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
12 Wolska N, Kassassir H, Luzak B, Watala C, Rozalski M. Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y12 Antagonists in a cAMP- and Calcium-Dependent Manner. Pharmaceuticals (Basel) 2020;13:E177. [PMID: 32752089 DOI: 10.3390/ph13080177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Wirsching E, Fauler M, Fois G, Frick M. P2 Purinergic Signaling in the Distal Lung in Health and Disease. Int J Mol Sci 2020;21:E4973. [PMID: 32674494 DOI: 10.3390/ijms21144973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
14 Müller CE, Baqi Y, Namasivayam V. Agonists and Antagonists for Purinergic Receptors. Methods Mol Biol 2020;2041:45-64. [PMID: 31646479 DOI: 10.1007/978-1-4939-9717-6_3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
15 Zarei M, Sahebi Vaighan N, Ziai SA. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. Immunopharmacol Immunotoxicol 2021;43:633-43. [PMID: 34647511 DOI: 10.1080/08923973.2021.1988102] [Reference Citation Analysis]
16 Hinwood M, Nyberg J, Leigh L, Gustavsson S, Attia J, Oldmeadow C, Ilicic M, Linden T, Åberg ND, Levi C, Spratt N, Carey LM, Pollack M, Johnson SJ, Kuhn GH, Walker FR, Nilsson M. Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries. BMJ Open 2022;12:e058244. [PMID: 35534077 DOI: 10.1136/bmjopen-2021-058244] [Reference Citation Analysis]
17 Baqi Y. Anthraquinone Dyes: A Synthetic and Chemical Characterization Protocol for an Industrial Chemistry Laboratory Course. J Chem Educ . [DOI: 10.1021/acs.jchemed.1c00865] [Reference Citation Analysis]
18 Hirata TDC, Dagli-Hernandez C, Genvigir FDV, Lauschke VM, Zhou Y, Hirata MH, Hirata RDC. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. Mol Diagn Ther 2021. [PMID: 34357562 DOI: 10.1007/s40291-021-00549-z] [Reference Citation Analysis]
19 Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci 2020;21:E1391. [PMID: 32092903 DOI: 10.3390/ijms21041391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
20 Li Y, Zhang Y, Cao B, Zhang F, Niu M, Bai X, Zhang M, Zhang H. Screening for the antiplatelet aggregation quality markers of Salvia yunnanensis based on an integrated approach. Journal of Pharmaceutical and Biomedical Analysis 2020;188:113383. [DOI: 10.1016/j.jpba.2020.113383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Vultaggio-poma V, Di Virgilio F. P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells. Biomolecules 2022;12:983. [DOI: 10.3390/biom12070983] [Reference Citation Analysis]
22 Baqi Y. Recent Advances in Microwave-Assisted Copper-Catalyzed Cross-Coupling Reactions. Catalysts 2021;11:46. [DOI: 10.3390/catal11010046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Schäkel L, Mirza S, Pietsch M, Lee SY, Keuler T, Sylvester K, Pelletier J, Sévigny J, Pillaiyar T, Namasivayam V, Gütschow M, Müller CE. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. Arch Pharm (Weinheim) 2021;:e2100300. [PMID: 34697820 DOI: 10.1002/ardp.202100300] [Reference Citation Analysis]
24 Xu D, Xie L, Zhang Z, Wang D, Qiu J, Yu W, Xu C, He C, Xu X, Yin J. Preliminary Investigation about the Expression of G Protein-Coupled Receptors in Platelets from Patients with Chronic Immune Thrombocytopenic Purpura. Acta Haematol 2021;144:551-9. [PMID: 33849009 DOI: 10.1159/000514907] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]